Drugs for Alzheimer's disease: best avoided. No therapeutic advantage.
The French Pharmacoeconomic Committee that assesses the medical benefit of new drugs and provides recommendations about reimbursement has downgraded its rating of the medical benefit (SMR, service mddical rendu) provided by cholinesterase inhibitors and memantine in Alzheimer's disease from "major" to "low".